Puma Biotechnology, Inc.
A biopharmaceutical company based in Los Angeles that develops and sells cancer treatments, best known for its breast-cancer drug Nerlynx, a pill given to adults with HER2-positive breast cancer to help stop the disease from returning. It was founded in 2010 by Alan Auerbach, the same entrepreneur behind the earlier Cougar Biotechnology, whose big-cat naming theme it kept: puma and cougar are simply two names for the same mountain lion, and the drug itself was licensed from Pfizer in 2011.
Granted 525.5K · Sold 198.2K
Granted 151.5K · Sold 55.8K
Granted 135.4K · Sold 41.8K
Granted 74.9K · Sold 31.0K
Granted 43.3K · Sold 8.0K
Granted 81.0K · Sold 26.1K
Granted 81.0K · Sold 34.2K
Granted 81.0K · Sold 68.4K
Granted 81.0K · Sold 39.1K
Granted 81.0K · Sold 48.6K
Granted 81.0K · Sold 66.0K
Granted 81.0K · Sold 81.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Auerbach Alan HPresident and CEO, Director, 10% owner · 12 transactions | +4.7% | 7.31M | 525.5K | — | 198.2K |
| Nougues Maximo FChief Financial Officer · 11 transactions | +66.3% | 240.0K | 151.5K | — | 55.8K |
| Hunt Douglas MSee Remarks · 11 transactions | +83.8% | 205.3K | 135.4K | — | 41.8K |
| Ludwig Jeffrey JeromeChief Commercial Officer · 6 transactions | +38.8% | 156.8Kas of Feb 2025 | 74.9K | — | 31.0K |
| Wong Alvin FChief Scientific Officer · 3 transactions | +33.3% | 141.2Kas of Feb 2024 | 43.3K | — | 8.0K |
| Stuglik Brian MDirector · 6 transactions | +93.1% | 113.9K | 81.0K | — | 26.1K |
| Dorval AllisonDirector · 6 transactions | +106.3% | 90.8K | 81.0K | — | 34.2K |
| Miller Michael PatrickDirector · 6 transactions | +18.5% | 81.0K | 81.0K | — | 68.4K |
| Cesano AlessandraDirector · 5 transactions | +155% | 68.8K | 81.0K | — | 39.1K |
| Wilson Troy EdwardDirector · 6 transactions | +6600% | 60.3K | 81.0K | — | 48.6K |
| Moyes Jay MDirector · 6 transactions | +34.6% | 58.3K | 81.0K | — | 66.0K |
| Senderowicz AdrianDirector · 6 transactions | — | 27.0K | 81.0K | — | 81.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -698.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.